NCT06223932View on ClinicalTrials.gov

Evaluation of the Efficacy and Safety of Molnupiravir Treatment in Mild/Moderate Covid-19 Patients.

Active, not recruitingOBSERVATIONAL
Enrollment

2,600

Participants

Timeline

Start Date

July 7, 2022

Primary Completion Date

February 29, 2024

Study Completion Date

February 29, 2024

Conditions
COVID-19SARS-CoV-2 Infection
Interventions
DRUG

Molnupiravir

COVID-19 diagnosed patients receiving molnupiravir will be evaluated to show if Molnupiravir is effective in reducing the combined outcome of hospitalization/death due to COVID-19 in the first 28 days when used in real life.

Trial Locations (8)

34093

Istanbul University, Istanbul Faculty of Medicine, Department of Infectious Disease, Istanbul

Unknown

Cerrahpasa Faculty of Medicine Infectious Disease Departament, Istanbul

Ankara City Hospital, Ankara

Ankara University Faculty of Medicine, Ankara

CAM and SAKURA Training and Research Hospital, Istanbul

Istanbul Haseki Training and Research Hospital, Istanbul

Koc University Hospital, Istanbul

Umraniye Training and Research Hospital, Istanbul

All Listed Sponsors
collaborator

MDX Klinik Araştırma Egitim ve Danismanlik Ltd. Sti.

UNKNOWN

lead

Serap Yavuz

OTHER